Eptinezumab for the preventive treatment of migraine.

Abstract

Our knowledge of the pathophysiology of migraine and the molecules implicated in the disorder have evolved over time. Among these, calcitonin gene-related peptide has shown a crucial role that led to the development of therapies specifically targeting the molecule. Four monoclonal antibodies targeting the calcitonin gene-related peptide pathway are currently available after the US FDA approval of eptinezumab for the indication of migraine prevention. This is the only one of the class to be administered intravenously. The pharmacology of eptinezumab and the four studies that led to the approval, two Phase II and two Phase III clinical trials, are reviewed in this paper. Eptinezumab has demonstrated efficacy, tolerability and safety in patients with episodic and chronic migraine. Studies including migraineurs who have failed previous preventives, and comparison with other options administered quarterly, as well as real-world experience data will all be welcome.

• Authors: María Dolores Villar-Martínez, David Moreno-Ajona, Peter J Goadsby
• Journal: Pain management (Pain Manag) Vol. 11 Issue 2 Pg. 113-121 (Mar 2021) ISSN: 1758-1877 [Electronic] England
• PMID: 33280422 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• eptinezumab
• Calcitonin Gene-Related Peptide

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage, pharmacology)
• Calcitonin Gene-Related Peptide (immunology)
• Humans
• Migraine Disorders (drug therapy, prevention & control)